Sylvia Findlay is Pharmaceuticals and Biotechnology Industry Analyst at Frost & Sullivan.
New age therapies
Why do the biotech ventures mange to have such promising drug candidates while pharmaceutical R&D is facing a drug deficit?
Spotlight: Market analysis Beating the blockbuster blues
FDA has tightened up the approval of new drugs, ensuring careful scrutiny of clinical data and stringent scanning to analyse the probable side-effects of a new drug